Skip to main content

NIH Archives

Functional seizures associated with stroke, psychiatric disorders in electronic health records study

Jan. 7, 2021—In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.

Read more


Study reveals new strategy for reducing tumor growth, metastasis

Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

Read more


Polymer protection for heart muscle

Dec. 14, 2020—Vanderbilt researchers demonstrate that the polymer P188 has promise as a therapy to prevent reperfusion injury — the cellular damage that occurs when blood flow returns after an ischemic event like a heart attack.

Read more


Model students: improving clinical decision-making

Dec. 10, 2020—Vanderbilt investigators have devised a system to alert health IT teams to deteriorating performance in clinical prediction models.

Read more


Exploiting viral vulnerabilities

Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

Read more


Study details early events of inflammatory response

Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.

Read more


A cohort for type 2 diabetes studies

Nov. 17, 2020—A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.

Read more


Imaging “biomarker” for Alzheimer’s disease progression

Nov. 16, 2020—Changes in connectivity in the brain’s white matter may be a novel neuroimaging biomarker for assessing Alzheimer’s disease progression.

Read more


New therapeutic target for lung cancer

Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.

Read more


New treatment for a rare obesity

Nov. 3, 2020—Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.

Read more


VUMC begins study of second COVID-19 vaccine

Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Read more


Histamine circuits in brain reward center

Oct. 29, 2020—Histamine — commonly associated with allergies — also has a signaling role in the brain’s reward center and may offer a novel target for treating addiction.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more